Trial Profile
A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Sirolimus; Tacrolimus; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 19 Jul 2021 Status changed from active, no longer recruiting to completed.
- 21 May 2021 Planned End Date changed from 1 Jul 2021 to 1 Oct 2021.
- 02 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Jul 2021.